Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. We assessed, from the perspective of the Spanish National Health Service, the cost-effectiveness of posaconazole vs fluconazole in preventing IFI. A decisionanalytic model was developed to assess the average per patient treatment costs, IFIs avoided, life-years gained (LYG) and incremental cost per LYG for each prophylactic treatment used (in euros at 2007 prices). Patients are assumed to have received either posaconazole or fluconazole. The probabilities of IFI, IFI-related death and death from other causes were obtained from a single clinical trial. Long-term mortality and costs were estimated from secondary sources. Posaconazole was associated with fewer IFIs (5.3 vs 9%), increased LYG (8.01 vs 7.78) and higher IFI-related costs (h11 585 vs h6 959) per patient compared with fluconazole. The incremental cost-effectiveness of posaconazole vs fluconazole was estimated at h20 246 per LYG. There was a 70% probability that posaconazole is cost-effective at a h30 000 per LYG threshold. In conclusion, compared with fluconazole, posaconazole prophylaxis is a cost-effective strategy for the prevention of IFI in patients with GVHD.
Introduction
Invasive fungal infection (IFI) continues to be a major cause of mortality and morbidity in allogeneic haematopoietic SCT (HSCT) recipients. 1, 2 Among the main risk factors for the development of IFI in these patients are the immunological status of the patient, the use of central venous catheters, presence and extent of chronic or acute GVHD, previous history of fungal infection and CMV infection. 3, 4 The main pathogens that cause IFI in HSCT patients are Aspergillus and Candida species. 5 In the case of invasive aspergillosis, the rates of mortality vary between 60 and 80%, 6, 7 although recent studies show that this mortality level has been decreasing over recent years. 1, 8 As for candidiasis, there has been an increase in the isolation and identification of non-albicans species over the past few years. 9 This increase is responsible for the majority of nosocomial infections originating from this pathogen, with rates of mortality up to around 42%, depending on the species. 10 The diagnosis and treatment of IFI consumes a large amount of available resources because of the costs of acquiring the antifungal medication, the extra costs of hospitalization, diagnostic costs, laboratory analyses and other complementary tests, as well as diagnosis and treatment of the adverse effects. In addition, there are the costs of therapeutic failure and recurrence, which require the administration of second-line antifungal agents. 11 These reasons, combined with the high mortality rate, account for the increased interest in the administration of antifungal prophylaxis for patients at high risk of IFI.
Two controlled clinical trials showed the efficacy and safety of fluconazole in the prevention of IFI in HSCT patients. 12, 13 Further, in one of these studies, 12 fluconazole reduced the mortality related to IFI, as well as the overall mortality in these patients. Hence, fluconazole has been considered as the standard antifungal chemoprophylaxis in patients receiving allogeneic HSCT for more than 10 years. 14, 15 Recently, posaconazole was shown to be similar to fluconazole in the prevention of IFI and better with respect to prevention of invasive aspergillosis, as well as to reduction of IFI-related mortality in allogeneic HSCT patients with GVHD. 16 Nonetheless, posaconazole has a higher drug acquisition cost compared with fluconazole.
Owing to the progressive increase in health-care costs and the limitations on available resources, it is important to determine the cost-effectiveness of both drugs to aid in health-care decision-making. The objective of this study was to assess the cost effectiveness of posaconazole vs fluconazole in the prevention of IFI in patients receiving HSCT with GVHD from the perspective of the Spanish National Health System. Spain is a country with 45 million inhabitants with access to universal public health care. The results of the analyses will be useful not only at the local level, but also at the European level for those countries that have a similar health service.
Methods

Overview of decision model
The study consisted of a pharmacoeconomic model, 17 based on a decision tree and a Markov model, which enabled simulations to be made of complex health-care processes for the prevention of IFI in patients with GVHD following a HSCT. The model simulates the costs and the clinical benefits obtained by the GVHD patients receiving posaconazole or fluconazole for the prevention of IFI. 16 Depending on the prophylaxis received, the model estimates the probability of developing an IFI, as well as the costs resulting from the prevention and the management of the IFI arising in each treatment group. The outcomes from the model shown as the numbers of IFI avoided and lifeyears gained (LYG) which, together with the estimations of the costs of each alternative treatment, enables the efficiency (incremental cost-effectiveness ratio) to be determined for each prophylactic treatment.
The model was programmed in MS Office Excel (version 2003) and took into account only the direct costs and health benefits as dictated by the Spanish National Health System. The time horizon considered for the analysis was 112 days (which was the duration of the clinical trial on which this analysis was based). The lifetime of the patient was also taken into consideration. For lifetime analysis, we applied a time adjustment (rate of discount) on costs and clinical benefits of 3% per annum. All the monetary units are expressed in euros at 2007 prices.
The model included a decision tree with a nested Markov model that simulates the progression of the disease from the selection of prophylaxis to the death of the patient whether or not as a consequence of the IFI or of the underlying disease, or from natural causes. Clinical events during the trial period (112 days) were captured in the decision tree, whereas subsequent events beyond this period were simulated in 1-month Markov cycles.
The model illustrated in Figure 1 starts with the selection of prophylaxis for IFI (posaconazole or fluconazole). On the basis of the treatment received, the model estimates the probability of acquiring an IFI and of dying from this cause once the IFI has occurred. The model considers the probability of dying from causes unrelated with the IFI during the prophylaxis (death from the underlying disease) in patients who do not acquire an IFI and also those who survival this infection.
Patients surviving the period of prophylaxis of 112 days are entered into a Markov model which, following monthly cycles, models the risk of death in the long term as a function of age, gender and underlying disease, but independent of whether or not there was IFI.
Clinical efficacy
Clinical efficacy used in the model were based on the results obtained in an international, multicentred, randomized, double-blind clinical trial in which the efficacy and safety of posaconazole and fluconazole were compared with respect to the prevention of IFI in patients with severe GVHD. 16 The patients (n ¼ 301) received either posaconazole (200 mg three times daily; total dose 600 mg/day) as an oral suspension, or fluconazole 400 mg once daily as capsules (n ¼ 299). The average treatment duration in each group was 112 days following the HSCT. At the end of this period, posaconazole was as effective as fluconazole in the prevention of IFI (incidence of 5.3 and 9.0%, respectively; odds ratio: 0.56; 95% confidence interval (95% CI): 0.30-1.07; P ¼ 0.07) and superior to fluconazole not only with respect to proven or probable invasive aspergillosis (2.3 vs 7.0%; odds ratio: 0.31; 95% CI: 0.13-0.75; P ¼ 0.006), but also in the number of deaths related with IFI (1.0% vs 4%; P ¼ 0.046). The incidence of adverse effects associated with the study medication was similar in both treatment groups (36% in the posaconazole group and 38% in the fluconazole group).
Survival during the prophylaxis was estimated based on the same clinical trial. 16 In this trial neither the rates of mortality following an IFI nor the mortality rates from the underlying disease showed statistically significant differences between posaconazole or fluconazole groups. Consequently, for this model it was assumed that the probability of death from IFI (37%) and the probability of death from causes unrelated to IFI (24%) were the same in both groups.
After the prophylaxis period, survival was estimated based on data from the published literature. The majority of patients in the clinical trial had acute GVHD grade 2 (45%), acute grade 3 (17%) or extensive chronic GVHD (33%). Patients had several underlying diseases, including CML (34% of patients), AML (25% of patients) and nonHodgkin's lymphoma (13% of patients).
Data on the survival among patients with GVHD are scarce in the literature and, where they exist, they vary widely. Death rates have been reported to differ depending on the type of GVHD. For the purposes of the model, it was assumed that if patients with acute GVHD survived the 112 day following initiation of prophylaxis, the death rate due to chronic GVHD may be applied as surviving acute GVHD puts a patient at high risk for chronic GVHD. 18 Wingard et al. 19 examined risk factors for death among patients who developed chronic GVHD following allogeneic BMT. As the patient population in the Wingard study was similar to the population in the clinical trial of posaconazole vs fluconazole (19% of patients with CML; 46% of patients with acute myelogenous leukaemia; 2% of patients with lymphoma), these values were used to estimate survival beyond 112 days for the patients in our model.
The Wingard study provides projected 10-year survival data after the onset of chronic GVHD. As mortality in the first 4 months is accounted for in our model using the Pharmacoeconomic evaluation of IFI prophylaxis in HSCT R de la Cámara et al
Ullman trial data, mortality from 4 months to 10 years was estimated for input into our model based on the Wingard study. To account for death not being constant over the 10-year time period, exponential smoothing was conducted to estimate annual excess mortality for GVHD patients, which resulted in an excess mortality rate of a 6%. The derived excess mortality annual rate was then applied to agespecific death rates for the general population, obtained from the Spanish Life Tables. 20 Baseline assumptions and references are presented in Table 1 .
Resource use and costs
The economic consequences of the options compared were calculated based on the mean direct costs of each of the prophylactic alternatives. Categories of costs included the cost of prophylaxis (costs of drug, administration and monitoring) and cost of managing an IFI if one develops.
The cost of each of the alternative drugs was calculated based on the acquisition of the drug at the manufacturer's ex-factory price (the price at which the drug is purchased by the hospital). The calculation was based on the medication data provided by the General Council of the Official College of Pharmacists. 21 Dosages and duration of treatment were according to the study published by Ullmann et al. 16 To calculate the cost of administration and monitoring of the drugs, we considered that a nurse would require 5 and 3 min to prepare and administer the dose of posaconazole and fluconazole, respectively, and that both drugs require monitoring liver function tests twice a week. The unit costs of these resources were obtained from the SOIKOS database for the year 2005 and updated to the year 2007 costs. This database records the cost of numerous public health-care resources published in the scientific literature, and enables reliable data to be obtained on unit costs for each resource consumed. 22 Finally, the costs of IFI management were obtained from an economic evaluation conducted in Spain assessing voriconazole vs conventional amphotericin B in the treatment of invasive aspergillosis. 23 The costs considered were direct costs of hospitalization, drug acquisition costs, laboratory analyses, and treatment of therapeutic failures. The resulting cost of the management of an IFI was around h63 359.30 (value updated to euros at 2007 prices). 23 Table 1 summarizes the costs of all the resources consumed with each of the two therapeutic alternatives.
The model did not consider the costs of adverse effects (extended hospital stay, greater use of analytical and complementary tests, and so on), nor the cost of the management of the underlying disease, as these were considered to be the same in the two groups.
Analyses performed
The number of IFI avoided and the number of LYG were calculated for each treatment group (posaconazole or Pharmacoeconomic evaluation of IFI prophylaxis in HSCT R de la Cámara et al fluconazole). Total costs were obtained for each treatment group, which included the costs of the prophylaxis and the treatment of the IFI. These data were used to calculate the incremental costs per IFI avoided and per LYG with posaconazole compared with that for fluconazole.
If strategy A is more efficacious and less expensive than strategy B, then strategy A 'dominates' strategy B and is termed 'dominant' (cost-saving). In such a case, it is not necessary to calculate the incremental cost-effectiveness ratio as this alternative will always lead to better clinical outcomes at lesser cost. 24 In other words, it will always be cost-saving. If, on the other hand, strategy A is more efficacious but more expensive than strategy B, then an incremental cost-effectiveness ratio is calculated. In Spain, a technology is considered cost-effective and adoptable, if the cost per LYG is oh30 000. 25 
Sensitivity analysis
The impact of changes in key parameters on the findings was assessed using univariate and multivariate sensitivity analyses. 26 The univariate sensitivity analysis varied parameters, such as the efficacy of prophylaxis, the risk of death from IFI, and varying the costs from 75% to a 125% of the initial value. The outcomes were re-analyzed with these modifications and included in the cost-effectiveness analysis. These variations in the efficacy of posaconazole vs fluconazole were performed with a 95% CI of the value of the odds ratio obtained in the clinical trial of Ullmann et al. 16 The multivariate sensitivity analysis was carried out using a second-order Monte Carlo simulation, which analyzed the degree of uncertainty of the parameters used in the model, especially their relationship to the efficacy of the treatments and the costs. The variations of the parameters and the distributions used in the multivariate analyses are shown in Table 2 .
Results
Results on clinical benefits
Invasive fungal infection per patient in the group treated with fluconazole was 0.09 compared with 0.053 in the group treated with posaconazole, which implies a mean of 0.037 infections avoided per patient. Similarly, treatment with posaconazole achieved better clinical outcomes with respect to an increase in the life expectancy of the patients, an increase in the LYG of 0.23 compared with the group treated with fluconazole.
Results on costs
The total costs of the group treated with fluconazole were h6959 per patient, of which h1257 were due to the cost of the drug for prophylaxis and h5702 was the cost of the treatment of the IFI that occurred ( Figure 2) . As for the group treated with posaconazole, the total cost of the treatment was h11 585 per patient, of which h8221 was due to the cost of the drug for prophylaxis and h3364 was due to the cost of treatment of the IFI that occurred (Figure 2 ).
Incremental cost-effectiveness ratio
Prophylaxis with posaconazole achieved an incremental cost-effectiveness ratio relative to fluconazole of h20 246 per LYG. As this value is below the threshold accepted for the recommendation for a health strategy in Spain (h30 000), prophylaxis with posaconazole is considered to be cost-effective. Table 3 summarizes the costs and benefits obtained for each of the two treatments compared.
Results of the univariate sensitivity analysis
The results of the univariate sensitivity analysis are presented in Figure 3 . As can be expected, the results suggest that the model is sensitive to the probability of experiencing an IFI with posaconazole. All variations made to the parameters entered in the model resulted in minimal changes in the incremental cost-effectiveness ratio of treatment with posaconazole, which indicates that the model is robust and stable.
Results of the multivariate sensitivity analyses A plot of the incremental costs vs incremental life years for 1000 simulations is shown in Figure 4 . The few points to the left of the vertical axis and above the horizontal axis indicate that there is a very small probability (1%) that posaconazole is dominated (that is, it is more costly and Pharmacoeconomic evaluation of IFI prophylaxis in HSCT R de la Cámara et al less effective) by the fluconazole strategy. The set of points to the right of the vertical axis and above the h30 000 per LYG threshold line indicates that there is also a possibility that posaconazole has an incremental cost-effectiveness ratio that is higher than h30 000 per LYG, relative to fluconazole. The majority of the points (70%) lie in the region where posaconazole has an incremental costeffectiveness ratio between h0 and h30 000 per LYG relative to fluconazole (the area above the horizontal axis and below the 30 000 per LYG threshold line).
Discussion
In the economic evaluation described here, a decision tree model was used to analyze the efficiency (incremental cost-effectiveness ratio) of antifungal prophylaxis with posaconazole or fluconazole in GVHD patients following HSCT and immunosuppressive treatment. Despite the higher costs of drug acquisition (h8221 vs h1257 posaconazole vs fluconazole), posaconazole is more effective (8.01 vs 7.78 LYG), resulting in a favourable costeffectiveness ratio for posaconazole (h20 246 per LYG). This amount falls within the accepted threshold (h30 000 per LYG, in Spain) for a new health technology to be considered efficient and, therefore, adoptable. The economic evaluation presented here has some limitations. The data on efficacy and the probabilities applied in the different branches of the model were obtained from only a single clinical trial and the resources used were estimated from data published in the literature, especially those related to the cost of management of IFI. Also not included in this analysis was the cost of the management of the adverse effects produced by the therapies under evaluation. However, given the similar incidence of adverse reactions in the two treatment groups, the inclusion of these costs would not have modified the final result. Similarly, the inclusion of the costs of management of the underlying disease considered equal in the two treatments, would not materially affect the final results. Unresolved issues are the impact of posaconazole prophylaxis on the development of fungal infections after the observation period described in the Ullman's study (24 weeks) and on the selection of resistant fungi. Longitudinal surveillance studies are warranted to know the long-term impact of posaconazole in IFI prevention, and therefore its final cost-effectiveness outcome.
Among the strengths of this analysis is the consistency with the preliminary communicated findings in the United States, 27 Canada, 28 Switzerland, 29 and in the Netherlands 30 These communications highlight the efficiency of posaconazole vs fluconazole in patients Pharmacoeconomic evaluation of IFI prophylaxis in HSCT R de la Cámara et al with GVHD following HSCT. All these studies show that posaconazole is a cost-effective alternative as the incremental cost-effectiveness ratio is below the limit established in all of these countries (that is, a mean value below the acceptable maximum threshold), for example, $15 700-$50 000 per LYG in the United States; CND$34 668- Input parameter modified Incremental cost-effectiveness ratio (cost per LYG) Figure 3 Results of the univariate sensitivity analysis. LYG, life year gained; IFI, invasive fungal infection; p(IFI) posaconazole, probability of acquiring IFI after the patient has received prophylaxis with posaconazole; p(IFI) fluconazole, probability of acquiring IFI after the patient has received prophylaxis with fluconazole; p(IFI death after IFI) posaconazole, probability of death from IFI after having received prophylaxis with posaconazole; p(IFI death after IFI) fluconazole, probability of death from IFI after having received prophylaxis with fluconazole; p(death other causes), probability of death from other causes not related to IFI; relative GVHD survival, relative survival of the patients with GVHD. Pharmacoeconomic evaluation of IFI prophylaxis in HSCT R de la Cámara et al CAN$50 000 per LYG in Canada; CHF 48 324-CHF 50 000 per LYG in Switzerland and h26 225-h50 000 per quality-adjusted life years in the Netherlands. Given that IFI causes an elevated morbidity and mortality in patients receiving immunosuppressive therapy, the implementation of prophylaxis in patients with high risk is a recommendable strategy 11, 14, 15 and should be taken into account especially in the prevention of invasive aspergillosis. 31 Owing to the limited resources available, especially within the ambit of a hospital, the different alternatives for the management of a disease has to be carefully evaluated with the objective of selecting the most efficient alternative for the health-care system. The analyses presented here can help in the decision-making process of selection of an antifungal prophylaxis at a hospital level.
An important tendency in recent years is the improvement in the prognosis of invasive aspergillosis. [32] [33] [34] An improving survival probably translates into increased costs for antifungal drugs and diagnostic/monitoring methods (CT, serial galactomannan). If the patient survives, he/she will require prolonged antifungal therapy and, in many cases, a secondary prophylaxis if more intensive treatment is going to be administered (more chemotherapy cycles or perform an SCT). Therefore, in the long term, with a background of improving survival in invasive aspergillosis, the strategies able to decrease aspergillosis incidence, like posaconazole prophylaxis, will become a more cost-effective strategy than those not able to decrease it, like fluconazole prophylaxis.
The conclusions from this model of decision analysis would need to be confirmed in a prospective pharmacoeconomic study comparing posaconazole vs fluconazole as prophylactic antifungal treatments.
In summary, this study shows that, despite the greater acquisition cost of posaconazole compared with fluconazole, antifungal prophylaxis with posaconazole for patients with GVHD and HSCT receiving immunosuppressive therapy is cost-effective. The incremental cost-effectiveness ratio of posaconazole of 20 246 per LYG makes it a viable alternative to fluconazole.
